BENLYSTA- belimumab injection, powder, lyophilized, for solution 
Human Genome Sciences, Inc.





for injection, for intravenous use only

What is the most important information I should know about BENLYSTA?

BENLYSTA can cause serious side effects. Some of these side effects may cause death. It is not known if BENLYSTA causes these serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while receiving BENLYSTA.

Infections. Symptoms of an infection can include:
● fever                                                ● urinating often
● chills                                                ● coughing up mucus
● pain or burning with urination        ● warm, red, or painful skin
                                                               or sores on your body
Heart Problems. Symptoms of heart problems can include:
● chest discomfort or pain               ● nausea
● shortness of breath                       ● dizziness
● cold sweats                                   ● discomfort in other areas of
                                                              the upper body
Mental health problems and suicide. Symptoms of mental health problems can include:
● thoughts of suicide or dying           ● new or worse depression
● attempt to commit suicide              ● acting on dangerous
● trouble sleeping (insomnia)           ● other unusual changes in
                                                               your behavior or mood
● new or worse anxiety                     ● thoughts of hurting yourself
                                                               or others


BENLYSTA is a prescription medicine used to treat adults with active systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.

BENLYSTA contains belimumab which is in a group of medicines called monoclonal antibodies. Lupus is a disease of the immune system (the body system that fights infection). People with active lupus often have high levels of a certain protein in their blood. BENLYSTA binds to and limits the activity of the protein. When given together with other medicines for lupus, BENLYSTA decreases lupus disease activity more than other lupus medicines alone.

It is not known if BENLYSTA is safe and effective in people with severe active lupus nephritis or severe active central nervous system lupus.
It is not known if BENLYSTA is safe and effective in children.

Do not receive BENLYSTA if you:

are allergic to belimumab or any of the ingredients in BENLYSTA. See the end of this Medication Guide for a complete list of ingredients in BENLYSTA.

Before you receive BENLYSTA, tell your healthcare provider about all of your medical conditions, including if you:

think you have an infection or have infections that keep coming back. You should not receive BENLYSTA if you have an infection unless your healthcare provider tells you to. See “What is the most important information I should know about BENLYSTA?”
have or have had mental health problems such as depression or thoughts of suicide.
have recently received a vaccination or if you think you may need a vaccination. If you are receiving BENLYSTA, you should not receive live vaccines.
are allergic to other medicines.
are receiving other biologic medicines, monoclonal antibodies or IV infusions of cyclophosphamide (CYTOXAN ®).
have or have had any type of cancer.
are pregnant or plan to become pregnant. It is not known if BENLYSTA will harm your unborn baby. Females who are able to become pregnant should talk to their healthcare provider about whether or not they will use birth control (contraception) and receive BENLYSTA. If BENLYSTA is recommended, you should use an effective method of birth control while receiving BENLYSTA and for at least 4 months after the final dose of BENLYSTA. Tell your healthcare provider right away if you become pregnant during your treatment with BENLYSTA or if you think you may be pregnant.
If you become pregnant while receiving BENLYSTA, talk to your healthcare provider about enrolling in the BENLYSTA Pregnancy Registry. You can enroll in this registry by calling 1-877-681-6296. The purpose of this registry is to monitor the health of you and your baby.
are breastfeeding or plan to breastfeed. It is not known if BENLYSTA passes into your breast milk. You and your healthcare provider should discuss whether or not you should receive BENLYSTA and breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of your medicines with you to show to your healthcare provider and pharmacist when you get a new medicine.

How will I receive BENLYSTA?

You will be given BENLYSTA by a healthcare provider through a needle placed in a vein (IV infusion). It takes about 1 hour to give you the full dose of BENLYSTA.
Your healthcare provider will tell you how often you should receive BENLYSTA.
Your healthcare provider may give you medicines before you receive BENLYSTA to help reduce your chance of having a reaction. A healthcare provider will watch you closely while you are receiving BENLYSTA and after your infusion for signs of a reaction.

What are the possible side effects of BENLYSTA?

BENLYSTA can cause serious side effects, including:

See “What is the most important information I should know about BENLYSTA?”
Cancer. BENLYSTA may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers.
Allergic (hypersensitivity) and infusion reactions. Serious allergic or infusion reactions can happen on the day of or days after receiving BENLYSTA and may cause death. Your healthcare provider will watch you closely while you are receiving BENLYSTA and after your infusion for signs of a reaction. Allergic reactions can sometimes be delayed; tell your healthcare provider right away if you have any of the following symptoms of an allergic or infusion reaction:
○    itching                                       ○    low blood pressure
○    swelling of the face, lips,          ○    dizziness or fainting
      mouth, tongue, or throat            ○    headache
○    trouble breathing                       ○    nausea
○    anxiousness                               ○    skin rash, redness, or swelling
Progressive multifocal leukoencephalopathy (PML). PML is a serious and life-threatening brain infection. Your chance of getting PML may be higher if you are treated with medicines that weaken your immune system, including BENLYSTA. PML can result in death or severe disability. If you notice any new or worsening medical problems such as those below, tell your healthcare provider right away:
○    memory loss                                ○    difficulty talking or walking
○    trouble thinking                           ○    loss of vision
○    dizziness or loss of balance

The most common side effects of BENLYSTA include:

○    nausea                                          ○    cough (bronchitis)
○    diarrhea                                        ○    trouble sleeping
○    fever                                             ○    leg or arm pain
○    stuffy or runny nose and              ○    depression
       sore throat (nasopharyngitis)       ○    headache

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of BENLYSTA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.

General information about the safe and effective use of BENLYSTA

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BENLYSTA for a condition for which it was not prescribed. This Medication Guide summarizes the most important information about BENLYSTA. You can ask your healthcare provider or pharmacist for information about BENLYSTA that is written for healthcare professionals.

What are the ingredients in BENLYSTA?

Active ingredient: belimumab.

Inactive ingredients: citric acid, polysorbate 80, sodium citrate, sucrose.

BENLYSTA is a registered trademark of the GSK group of companies. CYTOXAN is a trademark of the respective owner and is not a trademark of the GSK group of companies. The maker of this brand is not affiliated with and does not endorse the GSK group of companies or its products.

Manufactured by

Human Genome Sciences, Inc.

(a subsidiary of GlaxoSmithKline)

Rockville, Maryland 20850

U.S. License No. 1820

Marketed by


Research Triangle Park, NC 27709

For more information, go to or call 1-877-423-6597.

©2017 the GSK group of companies. All rights reserved.


This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: January 2017

Revised: 1/2017
Human Genome Sciences, Inc.